Spoken Alpha
Theriva Biologics, Inc.
Theriva Biologics develops oncolytic adenovirus therapies designed to treat solid tumors and other cancers. The company's lead candidate, VCN-01, is a genetically modified virus engineered to selectively replicate in tumor cells, express an enzyme that degrades tumor stroma to improve drug penetration, and trigger anti-tumor immune responses.
Theriva Biologics, Inc is a Healthcare company operating in Biotechnology with a $11.1M market cap.
TOVX missed consensus EPS by 0.4% in Q2 FY2026, reported Aug 10, 2026.
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TOVX.
$ curl https://api.spokenalpha.com/v1/companies/TOVXFAQ
Spoken Alpha indexes TOVX's earnings call transcripts at https://spokenalpha.com/companies/TOVX. Each call links to attributed speakers and parsed analyst Q&A. Theriva Biologics, Inc.'s own investor relations page is at https://therivabio.com/investors/.
Theriva Biologics, Inc. (TOVX) held its most recent earnings call on 2024-03-25, covering fiscal Q4 2023.
Theriva Biologics, Inc. (TOVX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | $-0.07 | $-0.05 | -40.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $-0.05 | $-0.05 | 0.0% | $300.0K | — | — | EODHD |
| Q4 FY2025 | 2026-03-11 | $-0.10 | $-0.37 | +73.5% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.45 | $-0.38 | -18.4% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-1.93 | $-0.47 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-13 | $-1.55 | $-1.56 | +0.6% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $-11.49 | $-7.22 | -59.1% | $154.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-6.81 | $-5.25 | -29.7% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-10.75 | $-4.75 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-7.50 | $-8.50 | +11.8% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-24 | $-0.34 | $-0.41 | +17.1% | $758.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-4.75 | $-8.50 | +44.1% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-8.50 | $-8.50 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-7.50 | $-8.00 | +6.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $-0.33 | $-0.33 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-8.25 | $-11.25 | +26.7% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-7.75 | $-7.50 | -3.3% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.30 | $-0.30 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-15 | $-10.00 | $-5.00 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-02 | $-5.00 | $-5.00 | 0.0% | $0 | — | — | EODHD |
Source: EODHD. TOVX reported actuals as published; sparse fields render as —.